TIDES Europe: Oligonucleotide and Peptide Therapeutics is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Meiling Li
Scientist at Hoffmann-La Roche

Profile

Dr. Meiling Li is a member of the RNA Therapeutics Group at F. Hoffmann-La Roche, Basel, Switzerland. Her current research area is on backbone-modified Locked Nucleic Acids with a particular focus on stereodefined phosphorothioates and phosphorodithioates. Dr. Li received her PhD from University of Oxford (UK) in organic chemistry. She then moved to the ETH Zurich as a postdoctoral fellow, joining the group of Prof. Jonathan Hall, where she developed the stereodefined synthesis of MOE-modified antisense oligonucleotides. In her current role she supports various drug discovery programs focusing on the lead optimization of LNA-based antisense oligonucleotides.

Meiling Li's Network

Agenda Sessions

  • Introduction of Non-chiral Phosphorodithioates into Locked Nucleic Acids

    , 16:00